GO:1904205 negative regulation of skeletal muscle hypertrophy: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904205 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of skeletal muscle hypertrophy.
• Myostatin (MSTN) is a secreted TGF-beta superfamily ligand that acts as a powerful negative regulator of muscle mass; its loss causes dramatic muscle overgrowth in mice.
• Activin type II receptors (ACVR2A/ACVR2B) mediate myostatin signaling, and their blockade enhances hypertrophy, confirming the pathway's role in negative regulation.
• MicroRNAs such as miR-1, miR-133, and miR-206 fine-tune the balance between hypertrophy and atrophy by targeting growth-related transcripts.
• Dysregulation of negative regulators contributes to sarcopenia, cachexia, and neuromuscular disorders, making them therapeutic targets.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in muscle hypertrophy.
Description
Skeletal muscle hypertrophy is the enlargement of muscle fibers due to increased contractile protein synthesis and satellite cell fusion, a process critical for strength, metabolism, and quality of life. The term GO:1904205, negative regulation of skeletal muscle hypertrophy, encompasses all molecular events that restrain this growth response, ensuring muscle homeostasis and preventing pathological overgrowth. Understanding these brakes is essential because their dysfunction underlies muscle wasting conditions such as sarcopenia and cachexia, and because manipulating them holds therapeutic potential for muscle regeneration. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of the negative regulation of skeletal muscle hypertrophy, covering its mechanisms, key genes, disease links, and state-of-the-art CRISPR methodologies for functional interrogation.
negative regulation of skeletal muscle hypertrophy At A Glance
| GO ID | GO:1904205 |
|---|---|
| GO term | negative regulation of skeletal muscle hypertrophy |
| Ontology | biological_process |
| Synonym | down regulation of skeletal muscle hypertrophy, down-regulation of skeletal muscle hypertrophy, downregulation of skeletal muscle hypertrophy, inhibition of skeletal muscle hypertrophy |
| Major function | Restrains skeletal muscle fiber enlargement by inhibiting anabolic signaling, promoting catabolism, or limiting satellite cell activity. |
| Key negative regulators | MSTN (myostatin), ACVR2A/ACVR2B, SMAD2/3, FOXO transcription factors, MuRF1, atrogin-1, myostatin-related microRNAs. |
| Upstream signals | TGF-beta superfamily ligands (myostatin, activins), glucocorticoids, inflammatory cytokines, and metabolic stress. |
| Physiological context | Maintains muscle mass homeostasis; prevents excessive growth; dysregulated in aging, disuse, and disease. |
What Is GO:1904205?
According to the Gene Ontology, GO:1904205 (negative regulation of skeletal muscle hypertrophy) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of skeletal muscle hypertrophy. In other words, it includes all cellular and molecular mechanisms that put the brakes on the enlargement of skeletal muscle fibers, whether by inhibiting protein synthesis, promoting protein degradation, or blocking satellite cell activation and fusion.
Why Is negative regulation of skeletal muscle hypertrophy Important in Cell Biology?
The negative regulation of skeletal muscle hypertrophy is fundamental to muscle homeostasis, and its perturbation is a common feature of muscle-wasting disorders. Myostatin, the prototypical negative regulator, was discovered through a knockout mouse that exhibited a dramatic increase in muscle mass, establishing the principle that secreted factors can limit muscle growth. Subsequent work showed that blocking activin type II receptors enhances hypertrophy, confirming that this pathway is a druggable target. Moreover, microRNAs and transcription factors fine-tune the hypertrophic response, and their dysregulation contributes to sarcopenia and cachexia. Thus, understanding GO:1904205 is essential for developing therapies that promote muscle regeneration while avoiding pathological overgrowth.
• Maintains muscle mass homeostasis by preventing excessive fiber enlargement.
• Dysregulation contributes to sarcopenia, the age-related loss of muscle mass and function.
• Implicated in cachexia, a wasting syndrome associated with cancer and chronic diseases.
• Myostatin inhibition is a therapeutic strategy for muscular dystrophies and other myopathies.
• MicroRNAs that negatively regulate hypertrophy are potential biomarkers and therapeutic targets.
• Satellite cell dysfunction in neuromuscular disorders involves altered negative regulation of hypertrophy.
• Exercise-induced muscle growth requires transient suppression of negative regulators.
• CRISPR screens can identify novel negative regulators, accelerating target discovery.
• Understanding these brakes helps optimize anabolic interventions in sports and rehabilitation.
• Animal models with mutations in negative regulators provide insights into muscle plasticity.
What Happens During negative regulation of skeletal muscle hypertrophy?
Initiation by TGF-beta superfamily ligands
In simple terms: Certain secreted proteins act like brakes on muscle growth by binding to receptors on muscle cells.
Negative regulation of skeletal muscle hypertrophy is often initiated by extracellular ligands of the TGF-beta superfamily, most notably myostatin (MSTN). Myostatin is produced and secreted by skeletal muscle cells and acts in an autocrine/paracrine manner to limit fiber growth. Other ligands such as activins and GDF11 can also activate this pathway. These ligands bind to activin type II receptors (ACVR2A/ACVR2B), which are serine/threonine kinases, leading to receptor activation and downstream signaling.
Intracellular signaling via SMAD2/3
In simple terms: Once the brake signal reaches the inside of the cell, it activates proteins that turn off growth genes.
Activated ACVR2A/ACVR2B phosphorylate and activate SMAD2 and SMAD3, which then form complexes with SMAD4 and translocate to the nucleus. In the nucleus, these complexes regulate transcription of target genes that inhibit muscle protein synthesis and promote protein degradation. For example, myostatin signaling upregulates the expression of atrogin-1 (FBXO32) and MuRF1 (TRIM63), E3 ubiquitin ligases that target contractile proteins for degradation. This transcriptional program effectively reduces the rate of hypertrophy.
Inhibition of mTORC1 and protein synthesis
In simple terms: The brake signal also directly dampens the cell's protein-building machinery.
Myostatin and related ligands inhibit the mTORC1 signaling pathway, a master regulator of protein synthesis and muscle hypertrophy. Specifically, SMAD2/3 activation can interfere with the Akt/mTOR axis, reducing phosphorylation of downstream effectors such as p70S6K and 4E-BP1, thereby decreasing translation initiation. This inhibition of protein synthesis is a key mechanism by which negative regulators prevent excessive muscle growth.
Modulation by microRNAs
In simple terms: Small RNA molecules act as fine-tuners of the brake system.
MicroRNAs (miRNAs) such as miR-1, miR-133, and miR-206 play critical roles in skeletal muscle biology and can either promote or inhibit hypertrophy. For instance, miR-1 and miR-206 target IGF-1 and other growth-promoting factors, thereby contributing to negative regulation. Conversely, miR-133 enhances hypertrophy by repressing negative regulators like myostatin. The balance between these miRNAs fine-tunes the hypertrophic response, and their dysregulation can tip the scale toward atrophy or excessive growth.
Integration with satellite cell dynamics
In simple terms: The brakes also control the stem cells that supply new nuclei to growing muscle fibers.
Satellite cells are muscle stem cells essential for postnatal muscle growth and regeneration. Negative regulators of hypertrophy can limit satellite cell activation, proliferation, and fusion, thereby restricting the addition of new myonuclei needed for fiber enlargement. For example, myostatin signaling inhibits satellite cell activation, and its blockade enhances satellite cell contribution to hypertrophy. Thus, negative regulation operates at both the level of protein synthesis in existing fibers and the recruitment of new nuclei from satellite cells.
Key Genes Involved in GO:1904205 negative regulation of skeletal muscle hypertrophy
The following genes and proteins are central to the negative regulation of skeletal muscle hypertrophy, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSTN | Secreted TGF-beta ligand that inhibits muscle growth | Knockout causes muscle hyperplasia/hypertrophy; target for muscle-wasting therapies. |
| ACVR2A | Activin receptor type IIA; mediates myostatin signaling | Blockade enhances hypertrophy; potential drug target. |
| ACVR2B | Activin receptor type IIB; mediates myostatin/activin signaling | Dual blockade with ACVR2A promotes maximal hypertrophy. |
| SMAD2 | Intracellular signal transducer downstream of TGF-beta receptors | Phosphorylation by ACVR2A/B activates catabolic genes. |
| SMAD3 | Intracellular signal transducer; forms complexes with SMAD4 | Regulates transcription of atrophy-related genes. |
| SMAD4 | Common mediator SMAD; partners with SMAD2/3 | Central node in TGF-beta signaling to inhibit hypertrophy. |
| FOXO1 | Forkhead transcription factor; promotes atrophy | Activated by myostatin; induces MuRF1 and atrogin-1. |
| FOXO3 | Forkhead transcription factor; promotes protein degradation | Key mediator of catabolic signaling in muscle. |
| FBXO32 | Atrogin-1; E3 ubiquitin ligase | Targets contractile proteins for degradation; negatively regulates hypertrophy. |
| TRIM63 | MuRF1; E3 ubiquitin ligase | Degrades myosin and other sarcomeric proteins; marker of atrophy. |
| MIR1-1 | MicroRNA-1; targets IGF-1 and other growth factors | Inhibits hypertrophy; dysregulated in muscle disease. |
| MIR133A1 | MicroRNA-133a; represses myostatin and other negative regulators | Promotes hypertrophy; potential therapeutic. |
| MIR206 | MicroRNA-206; targets IGF-1 and connexin43 | Inhibits hypertrophy; involved in regeneration. |
| IGF1 | Insulin-like growth factor 1; promotes hypertrophy | Negatively regulated by myostatin and miRNAs. |
| AKT1 | Serine/threonine kinase; activates mTORC1 | Inhibited by myostatin signaling; central to hypertrophy. |
| MTOR | Mechanistic target of rapamycin; master regulator of protein synthesis | Inhibited by negative regulators; key node. |
| HSF1 | Heat shock factor 1; protects against sarcopenia | Its decline may relieve negative regulation? Actually HSF1 alleviates sarcopenia, so it opposes negative regulation. |
| SIRT3 | Mitochondrial deacetylase; part of HSF1-SIRT3-PGC1α axis | Alleviates age-related muscle decline; opposes negative regulation. |
How Is negative regulation of skeletal muscle hypertrophy Regulated?
The negative regulation of skeletal muscle hypertrophy is itself tightly regulated at multiple levels. Upstream, the expression and secretion of myostatin are influenced by exercise, nutrition, and hormonal status. For instance, resistance exercise transiently reduces myostatin mRNA, allowing hypertrophy to proceed. Intracellularly, the pathway is modulated by inhibitory SMADs (SMAD6/7), which can block receptor-mediated signaling. Additionally, microRNAs such as miR-133a repress myostatin expression, providing a feed-forward mechanism to promote growth. Post-translational modifications, including phosphorylation and ubiquitination, regulate the stability and activity of SMADs and FOXO transcription factors. Finally, crosstalk with other signaling pathways, such as the IGF-1/Akt/mTOR axis, determines the net outcome on muscle mass.
negative regulation of skeletal muscle hypertrophy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MSTN | Sarcopenia, cachexia, muscular dystrophy | MSTN knockout mouse; AAV-mediated overexpression of dominant-negative myostatin. |
| ACVR2B | Muscle wasting, dystrophy | ACVR2B knockout or soluble decoy receptor (ActRIIB-Fc) in mice. |
| FOXO3 | Cachexia, atrophy | Muscle-specific FOXO3 knockout or overexpression in mice. |
| HSF1 | Age-related sarcopenia | HSF1 knockout and transgenic mice; SIRT3-PGC1α axis. |
| MIR133A1 | Muscle hypertrophy disorders | miR-133a transgenic or knockout mice; AAV delivery. |
Sarcopenia and age-related muscle loss
Sarcopenia is characterized by progressive loss of muscle mass and strength with aging. Recent evidence indicates that HSF1 alleviates age-associated sarcopenia and mitochondrial function decline via the SIRT3-PGC1α axis, suggesting that enhancing this protective pathway can counteract negative regulators of hypertrophy. Moreover, dysregulation of myostatin signaling contributes to sarcopenia, and its inhibition has been proposed as a therapeutic strategy.
Cachexia and cancer-associated muscle wasting
Cachexia is a multifactorial syndrome marked by severe muscle loss, often driven by inflammatory cytokines and tumor-derived factors that activate catabolic pathways. Negative regulators such as myostatin and FOXO transcription factors are upregulated in cachexia, promoting protein degradation and inhibiting hypertrophy. Targeting these pathways, for example with anti-myostatin antibodies, is under investigation to preserve muscle mass in cancer patients.
Neuromuscular disorders and satellite cell dysfunction
In neuromuscular disorders such as Duchenne muscular dystrophy, chronic degeneration and regeneration lead to satellite cell exhaustion and impaired hypertrophy. Negative regulators of hypertrophy, including myostatin, are often elevated and contribute to disease progression. Blocking activin type II receptors has been shown to enhance muscle mass in dystrophic models, highlighting the therapeutic potential of manipulating GO:1904205.
From negative regulation of skeletal muscle hypertrophy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene enhance muscle hypertrophy? | CRISPR knockout in C2C12 myotubes or mouse satellite cells; in vivo knockout via AAV-CRISPR. |
| Does a specific point mutation in a negative regulator alter its function? | CRISPR point mutation (e.g., kinase-dead ACVR2B) in myoblasts; assess downstream SMAD phosphorylation. |
| Does a disease-associated variant affect negative regulation? | Knock-in of the variant using CRISPR in mice or human iPSC-derived myotubes; measure hypertrophy markers. |
| Where and when is a negative regulator expressed? | Tagged knock-in (e.g., GFP or HA) using CRISPR; imaging and co-IP. |
| Does overexpression of a negative regulator block hypertrophy? | CRISPR activation (CRISPRa) or lentiviral overexpression in muscle cells; measure myotube diameter. |
| Can we identify novel negative regulators in a high-throughput manner? | Genome-wide CRISPR knockout or activation screen in myoblasts under hypertrophic stimuli. |
How to Study the negative regulation of skeletal muscle hypertrophy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript abundance | Identify genes differentially expressed upon negative regulator knockout. |
| Ribo-seq | Genome-wide translation efficiency | Assess inhibition of protein synthesis by myostatin. |
| Phosphoproteomics | Phosphorylation status of signaling proteins | Map SMAD2/3 and mTOR pathway changes. |
| Immunofluorescence | Protein localization and myofiber size | Quantify hypertrophy in vitro and in vivo. |
| CRISPR knockout screen | Loss-of-function phenotypes at scale | Discover novel negative regulators. |
| CRISPR activation screen | Gain-of-function phenotypes at scale | Identify suppressors of hypertrophy. |
| Western blot | Protein expression and phosphorylation | Validate signaling changes. |
| qRT-PCR | mRNA levels of target genes | Measure myostatin, atrogin-1, MuRF1. |
Transcriptomic and proteomic profiling
RNA-seq and proteomics can reveal global changes in gene and protein expression when negative regulators are manipulated. For example, comparing wild-type and myostatin-knockout muscle identifies downstream targets and pathways. Phosphoproteomics can uncover signaling nodes such as SMAD2/3 and mTOR substrates.
Ribosome profiling (Ribo-seq)
Ribo-seq measures translation efficiency genome-wide, providing insights into how negative regulators inhibit protein synthesis. This is particularly useful to dissect the acute effects of myostatin on translation initiation.
Imaging and morphometry
Immunofluorescence and confocal microscopy can quantify myofiber cross-sectional area, myonuclear number, and satellite cell fusion. These methods are standard for assessing hypertrophy in vitro and in vivo.
CRISPR screens and functional genomics
Pooled CRISPR knockout or activation screens in muscle cells can identify novel negative regulators of hypertrophy. Hits can be validated individually using the models described above.
How CRISPR Can Be Used to Study GO:1904205 negative regulation of skeletal muscle hypertrophy
Knockout
CRISPR knockout is used to delete negative regulator genes such as MSTN, ACVR2B, or FOXO3 in muscle cells or animal models. This approach can reveal whether the gene is necessary to restrain hypertrophy. For example, MSTN knockout mice exhibit dramatic muscle overgrowth, confirming its role. In vitro, knockout of ACVR2B in C2C12 cells enhances myotube formation.
Point Mutation
Point mutations can be introduced to dissect specific domains or phosphorylation sites. For instance, mutating the kinase domain of ACVR2B can render it inactive, mimicking a loss-of-function allele. CRISPR base editing or HDR can create such mutations in endogenous loci, allowing study of signaling mechanisms without confounding effects of complete knockout.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) or disease-associated variants enables tracking of protein expression, localization, and function. For example, knocking in a GFP tag at the MSTN locus allows visualization of myostatin secretion in live cells. Knock-in of human variants in mouse models can model disease susceptibility.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive high-level expression of negative regulators to test sufficiency. Overexpressing myostatin in muscle cells inhibits hypertrophy, while overexpressing miR-133a promotes it by repressing myostatin. These approaches complement loss-of-function studies.
How EDITGENE Supports negative regulation of skeletal muscle hypertrophy Research
Researchers studying negative regulation of skeletal muscle hypertrophy-related genes often need to determine whether a candidate gene is causally involved in restraining muscle growth, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and high-throughput screens.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of skeletal muscle hypertrophy research.
Frequently Asked Questions About negative regulation of skeletal muscle hypertrophy
What is GO:1904205?
GO:1904205 is the Gene Ontology term for negative regulation of skeletal muscle hypertrophy, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of skeletal muscle hypertrophy.
What genes are involved in negative regulation of skeletal muscle hypertrophy?
Key genes include MSTN (myostatin), ACVR2A, ACVR2B, SMAD2/3, FOXO1/3, FBXO32 (atrogin-1), TRIM63 (MuRF1), and microRNAs such as miR-1, miR-133a, and miR-206.
How does myostatin inhibit muscle growth?
Myostatin binds to activin type II receptors, activating SMAD2/3 signaling, which inhibits mTORC1 and protein synthesis while promoting protein degradation via atrogin-1 and MuRF1.
What is the role of microRNAs in negative regulation of skeletal muscle hypertrophy?
MicroRNAs such as miR-1 and miR-206 target growth-promoting factors like IGF-1, while miR-133a represses myostatin, thereby fine-tuning the hypertrophic response.
Which diseases are linked to dysregulated negative regulation of skeletal muscle hypertrophy?
Sarcopenia, cachexia, and neuromuscular disorders such as Duchenne muscular dystrophy involve altered negative regulation, contributing to muscle wasting.
How can CRISPR be used to study negative regulation of skeletal muscle hypertrophy?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of specific genes and to identify novel regulators through screens.
What are the best cell models for studying skeletal muscle hypertrophy?
C2C12 myoblasts, primary satellite cells, and human iPSC-derived myotubes are commonly used, along with in vivo mouse models.
What is the role of satellite cells in negative regulation of hypertrophy?
Satellite cells are muscle stem cells that contribute new nuclei to growing fibers; negative regulators can limit their activation and fusion, thereby restricting hypertrophy.
How does exercise affect negative regulators of muscle hypertrophy?
Resistance exercise transiently reduces myostatin expression and alters microRNA levels, relieving the brakes on hypertrophy and allowing muscle growth.
What methods are used to measure negative regulation of skeletal muscle hypertrophy?
Methods include RNA-seq, Ribo-seq, phosphoproteomics, immunofluorescence for myofiber size, and CRISPR screens to identify regulators.
Conclusion
The negative regulation of skeletal muscle hypertrophy (GO:1904205) is a critical biological process that maintains muscle homeostasis by restraining excessive growth. Key players such as myostatin, activin receptors, SMAD transcription factors, and microRNAs form a complex network that integrates extracellular cues and intracellular signaling to fine-tune muscle mass. Dysregulation of this network contributes to sarcopenia, cachexia, and neuromuscular disorders, making it a prime therapeutic target. Advances in CRISPR technology, including knockout, point mutation, knock-in, and overexpression models, are empowering researchers to dissect these mechanisms with unprecedented precision. EDITGENE stands ready to support these efforts with tailored CRISPR services and bioinformatics expertise.
References
- 1. Schiaffino S et al.. 2021. Molecular Mechanisms of Skeletal Muscle Hypertrophy.. J Neuromuscul Dis 8(2):169-183 PMID: 33216041
- 2. Morvan F et al.. 2017. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.. Proc Natl Acad Sci U S A 114(47):12448-12453 PMID: 29109273
- 3. Schiaffino S et al.. 2013. Mechanisms regulating skeletal muscle growth and atrophy.. FEBS J 280(17):4294-314 PMID: 23517348
- 4. McPherron AC et al.. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.. Nature 387(6628):83-90 PMID: 9139826
- 5. Tipton KD et al.. 2001. Exercise, protein metabolism, and muscle growth.. Int J Sport Nutr Exerc Metab 11(1):109-32 PMID: 11255140
- 6. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 7. Zhang J et al.. 2026. Skeletal Muscle HSF1 Alleviates Age-Associated Sarcopenia and Mitochondrial Function Decline via SIRT3-PGC1α Axis.. Adv Sci (Weinh) 13(11):e10368 PMID: 41400028
- 8. Hitachi K et al.. 2013. Role of microRNAs in skeletal muscle hypertrophy.. Front Physiol 4:408 PMID: 24474938
